Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
Items 201–300 of 1,000
Kassab, A. E., & Gedawy, E. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.026 · Cited by 83
Pyridine-Ureas as Potential Anticancer Agents: Synthesis and In Vitro Biological Evaluation
El-Naggar, M. H., Almahli, H., Ibrahim, H. S., Eldehna, W. M., & Abdel‐Aziz, H. A. (2018) · Molecules · doi:10.3390/molecules23061459 · Cited by 83
Elsawi, A. E., Elbadawi, M. M., Nocentini, A., Almahli, H., Giovannuzzi, S., Shaldam, M. A., Salem, R., Ibrahim, T. M., Abdel‐Aziz, H. A., Supuran, C. T., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00721 · Cited by 83
Dhar, S., Nygren, P., Csóka, K., Botling, J., Nilsson, K., & Larsson, R. L. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.453 · Cited by 83
Pinney, K. G., Mejia, M. P., Villalobos, V. M., Rosenquist, B. E., Pettit, G. R., Verdier‐Pinard, P., & Hamel, E. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00176-0 · Cited by 83
Das, U., Alcorn, J., Shrivastav, A., Sharma, R. K., Clercq, E. D., Balzarini, J. M., & Dimmock, J. R. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.08.002 · Cited by 82
Rickardson, L., Fryknäs, M., Dhar, S., Lövborg, H., Gullbo, J., Rydåker, M., Nygren, P., Gustafsson, M. G., Larsson, R., & Isaksson, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602699 · Cited by 82
Singla, P., Luxami, V., & Paul, K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.088 · Cited by 82
Raj, K. K. V., Narayana, B., Ashalatha, B. V., Kumari, S., & Sarojini, B. K. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.09.010 · Cited by 81
Farag, A. M., Ali, K. A. K., Eldebss, T. M. A., Mayhoub, A. S., Amr, A. E. E., Abdel‐Hafez, N. A., & Abdulla, M. M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.054 · Cited by 81
Al-Suwaidan, I. A., Abdel‐Aziz, A. A. ‐., Shawer, T. Z., Ayyad, R. R. A., Alanazi, A. M., Morsy, A. M. E., Mohamed, M. A., Abdel-Aziz, N. I., El‐Sayed, M. A. ‐., & El‐Azab, A. S. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2015.1004059 · Cited by 80
Amagata, T., Rath, C. M. B., Rigot, J. F., Tarlov, N., Tenney, K., Valeriote, F. A., & Crews, P. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030090t · Cited by 80
Paul, K., Sharma, A., & Luxami, V. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.005 · Cited by 80
Amăriucăi-Mantu, D., Antoci, V., Moldoveanu, C. C., Zbancioc, G. N., & Mangalagiu, I. I. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1190711 · Cited by 79
Tawfik, H. O., Petreni, A., Supuran, C. T., & El‐Hamamsy, M. H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114190 · Cited by 79
Wu, X., Zhou, N., Chen, Y., Sun, J., Lu, L., Chen, Q., & Zuo, C. (2024) · Light Science & Applications · doi:10.1038/s41377-024-01568-1 · Cited by 79
Rathish, I. G., Javed, K., Ahmad, S., Bano, S., Alam, M. S., Akhter, M., Pillai, K. K., Ovais, S., & Samim, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.026 · Cited by 79
Rostom, S. A. F., Badr, M. H., Razik, H. A. A. E., Ashour, H. M. A., & Wahab, A. E. A. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201100077 · Cited by 79
Structure-activity relationship approaches and applications
Tong, W., Welsh, W. J., Shi, L. M., Fang, H., & Perkins, R. (2003) · Environmental Toxicology and Chemistry · doi:10.1897/01-198 · Cited by 85
de Oliveira, J. F., Lima, T. S., Costa, D. B. V., Pedrosa, S. C. B. D. L., Lafayette, E. A., da Silva, R. M. F., de Almeida, S. M. V., de Moura, R. O., Ruiz, A. L. T. G., de Carvalho, J. E., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.023 · Cited by 78
Hafez, H. N., & El-Gazzar, A.-R. B. A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.126 · Cited by 78
Spiroxins, DNA cleaving antitumor antibiotics from a marine-derived fungus
McDonald, L. A., Abbanat, D. R., Barbieri, L. R., Bernan, V. S., Discafani, C. M., Greenstein, M. D., Janota, K., KORSHALLA, J. D., Lassota, P., Tischler, M., et al. (1999) · Tetrahedron Letters · doi:10.1016/s0040-4039(99)00242-7 · Cited by 78
Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore
McNulty, J., Mao, J., Gibe, R., Mo, R., Wolf, S., Pettit, G. R., Herald, D. L., & Boyd, M. R. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00614-4 · Cited by 78
Self-citationFadeyi, O., Adamson, S. T., Myles, E. L., & Okoro, C. O. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.078 · Cited by 77
Jarak, I., Kralj, M., Piantanida, I., Šuman, L., Žinić, M., Pavelić, K., & Karminski-Zamola, G. M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.004 · Cited by 77
Rashid, M., Husain, A., Mishra, R., Karim, S., Khan, S., Ahmad, M., Al-wabel, N., Husain, A., Ahmad, A., & Khan, S. A. (2015) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2015.08.019 · Cited by 78
Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives
Congiu, C., Onnis, V., Vesci, L., Castorina, M., & Pisano, C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.037 · Cited by 76
Kiselev, E., Dexheimer, T. S., Pommier, Y. G., & Cushman, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101048k · Cited by 76
Wang, H., Han, H., & Von Hoff, D. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4602 · Cited by 73
Trapani, G., Franco, M., Latrofa, A., Reho, A., & Liso, G. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00173-7 · Cited by 76
Grant, G. M., Giambernardi, T. A., Grant, A. M. S., & Klebe, R. J. (1999) · Matrix Biology · doi:10.1016/s0945-053x(99)00003-7 · Cited by 76
Shaaban, M. R., Saleh, T. S., Mayhoub, A. S., & Farag, A. M. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.033 · Cited by 75
Synthesis and anticancer activity evaluation of new 1,2,3-triazole-4-carboxamide derivatives
Pokhodylo, N. T., Shyyka, O. Y., & Matiychuk, V. S. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0841-8 · Cited by 75
Issa, D. A. E., Habib, N. S., & Wahab, A. E. A. (2014) · MedChemComm · doi:10.1039/c4md00257a · Cited by 75
Alanazi, A. M., Abdel‐Aziz, A. A. ‐., Al-Suwaidan, I. A., Abdel‐Hamide, S. G., Shawer, T. Z., & El‐Azab, A. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.029 · Cited by 75
Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents
Kachaeva, M. V., Hodyna, D. M., Semenyuta, I. V., Pilyo, S. G., Prokopenko, V. M., Kovalishyn, V., Metelytsia, L. O., & Броварец, В. С. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.04.006 · Cited by 75
Design and synthesis of new 2,5-disubstituted-1,3,4-oxadiazole analogues as anticancer agents
Agarwal, M., Singh, V., Sharma, S. K., Sharma, P., Ansari, M. Y., Jadav, S. S., Yasmin, S., Sreenivasulu, R., Hassan, M. Z., Saini, V., et al. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1672-1 · Cited by 74
Al-Suwaidan, I. A., Alanazi, A. M., Abdel‐Aziz, A. A. ‐., Mohamed, M. A., & El‐Azab, A. S. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.056 · Cited by 74
Khan, I. A., Ibrar, A., & Abbas, N. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201300231 · Cited by 77
Dumdei, E. J., Blunt, J. W., Munro, M. H. G., & Pannell, L. K. (1997) · The Journal of Organic Chemistry · doi:10.1021/jo961745j · Cited by 73
Kulcsár, M. J., Molčanov, K., Kojić‐Prodić, B., Bellotto, L., Kralj, M., Zani, F., & Tušek‐Božić, L. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.03.011 · Cited by 73
Gangjee, A., Zhao, Y., Lin, L., Raghavan, S., Roberts, E. G., Risinger, A. L., Hamel, E., & Mooberry, S. L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101010n · Cited by 74
Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives
Hung, J. M., Arabshahi, H. J., Leung, E. Y., Reynisson, J., & Barker, D. L. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.001 · Cited by 75
Egert‐Schmidt, A., Dreher, J., Dunkel, U., Kohfeld, S., Preu, L., Weber, H., Ehlert, J. E., Mutschler, B., Totzke, F., Schächtele, C., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901388c · Cited by 72
Hassan, G. S., El‐Messery, S. M., Al-Omary, F. A. M., Al‐Rashood, S. T., Shabayek, M. I., Abulfadl, Y. S., Habib, E. E., El-hallouty, S. M., Fayad, W., Mohamed, K. M., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.05.039 · Cited by 72
Al-Warhi, T. I., Elbadawi, M. M., Bonardi, A., Nocentini, A., Al-Karmalawy, A. A., Aljaeed, N., Alotaibi, O. J., Abdel‐Aziz, H. A., Supuran, C. T., & Eldehna, W. M. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2124409 · Cited by 71
The Cytotoxicity of Methyl Protodioscin Against Human Cancer Cell Lines In Vitro
Hu, K., & Yao, X. (2003) · Cancer Investigation · doi:10.1081/cnv-120018230 · Cited by 71
El-Hawash, S. A., Wahab, A. E. A., & Demellawy, M. E. (2006) · Archiv der Pharmazie · doi:10.1002/ardp.200500161 · Cited by 71
Cytotoxic potential of C-prenylated flavonoids
Šmejkal, K. (2013) · Phytochemistry Reviews · doi:10.1007/s11101-013-9308-2 · Cited by 73
Cytotoxic 2,6-bis(arylidene)cyclohexanones and related compounds
Dimmock, J. R., Kumar, P., Nazarali, A. J., Motaganahalli, N. L., Kowalchuk, T. P., Beazely, M. A., Quail, J. W., Oloo, E. O., Allen, T. M., Szydlowski, J., et al. (2000) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(00)01173-9 · Cited by 70
Reinhold, W. C., Mergny, J., Liu, H., Ryan, M., Pfister, T. D., Kinders, R. J., Parchment, R. E., Doroshow, J. H., Weinstein, J. N., & Pommier, Y. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3528 · Cited by 70
2-Substituted paullones: CDK1/cyclin B-inhibiting property and in vitro antiproliferative activity
Kunick, C., Schultz, C., Lemcke, T., Zaharevitz, D. W., Gussio, R., Jalluri, R. K., Sausville, E. A., Leost, M., & Meijer, L. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00048-2 · Cited by 86
Al-Warhi, T. I., Abo-Ashour, M. F., Almahli, H., Alotaibi, O. J., Al-Sanea, M. M., Al-Ansary, G. H., Ahmed, H. Y., Elaasser, M. M., Eldehna, W. M., & Abdel‐Aziz, H. A. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1773814 · Cited by 69
Gabr, M. T., El‐Gohary, N. S., El‐Bendary, E. R., & El‐Kerdawy, M. M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.097 · Cited by 71
Rostom, S. A. F. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.02.006 · Cited by 69
Girgis, A. S. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.09.007 · Cited by 69
Bradshaw, T. D., Chua, M.-S., Browne, H. L., Trapani, V., Sausville, E. A., & Stevens, M. F. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600225 · Cited by 69
Çıkla‐Süzgün, P., Özsavcı, D., Özakpınar, Ö. B., Şener, A., Çevik, Ö. D., Özbaş‐Turan, S., Akbuğa, J., Şahin, F., & Küçükgüzel, Ş. G. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201200449 · Cited by 76
El‐Dash, Y., Elzayat, E. M., Abdou, A. M., & Hassan, R. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105137 · Cited by 70
Synthesis, antitumour activity and structure–activity relationships of 5H-benzo[b]carbazoles
Asche, C., Frank, W. C., Albert, A., & Kucklaender, U. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.10.038 · Cited by 68
Ciavatta, M. L., Lefranc, F., Carbone, M., Mollo, E., Gavagnin, M., Betancourt, T., Dasari, R., Kornienko, A., & Kiss, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21423 · Cited by 75
Hassan, G. S., El‐Messery, S. M., Al-Omary, F. A. M., & El‐Subbagh, H. I. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.095 · Cited by 67
El-Deeb, I. M., Bayoumi, S. M., El‐Sherbeny, M. A., & Abdel‐Aziz, A. A. ‐. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.038 · Cited by 67
Novel 1,3,4-heterodiazole analogues: Synthesis and in-vitro antitumor activity
Taher, A. T., Georgey, H. H., & El‐Subbagh, H. I. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.11.013 · Cited by 67
Grem, J. L., Danenberg, K. D., Behan, K. A., Parr, A. L., Young, L., Danenberg, P. V., Nguyen, D. H. V., Drake, J., Monks, A. P., & Allegra, C. J. (2001) · PubMed · Cited by 67
Synthesis and Antitumor Activity of Some Curcumin Analogs
Youssef, K. M., & El‐Sherbeny, M. A. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200400939 · Cited by 66
Salahuddin, S., Yar, M. S., Mazumder, A., & Ahsan, M. J. (2013) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2013.02.001 · Cited by 66
Svingen, P. A., Loegering, D. A., Rodriquez, J., Meng, X. W., Mesner, P. W., Holbeck, S. L., Monks, A. P., Krajewski, S., Scudiero, D. A., Sausville, E. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0778-02 · Cited by 71
*Semisynthesis and cytotoxic activities of andrographolide analogues
Jada, S. R., Hamzah, A. S., Lajis, N. H., Saad, M. S., Stevens, M. F. G., & Stanslas, J. (2006) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360500499988 · Cited by 66
Sangshetti, J. N., Pathan, S. K., Patil, R. B., Ansari, S. A., Chhajed, S. S., Arote, R. B., & Shinde, D. B. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.050 · Cited by 66
Caruso, F., Rossi, M., Tanski, J. M., Pettinari, C., & Marchetti, F. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204690 · Cited by 66
Коваленко, С. І., Носуленко, И. С., Воскобойнік, О. Ю., Берест, Г. Г., Antipenko, L. N., Антипенко, А. Н., & Katsev, A. M. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0257-x · Cited by 65
Zerumbone, an HIV-Inhibitory and Cytotoxic Sesquiterpene of Zingiber Aromaticum and Z. Zerumbet
Dai, J., Cardellina, J. H., Mahon, J. B. M., & Boyd, M. R. (1997) · Natural product letters · doi:10.1080/10575639708043725 · Cited by 65
Self-citationSynthesis, single crystal and antitumor activities of benzimidazole–quinazoline hybrids
Sharma, A., Luxami, V., & Paul, K. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.107 · Cited by 65
Slade, D., Galal, A. M., Gul, W., Radwan, M. M., Ahmed, S. A., Khan, S. I., Tekwani, B. L., Jacob, M. R., Ross, S. A., & ElSohly, M. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.019 · Cited by 68
A new domino-Knoevenagel–hetero-Diels–Alder reaction
Matiychuk, V. S., Lesyk, R., Obushak, M. D., Gzella, A. K., Atamanyuk, D. V., Ostapiuk, Y. V., & Kryshchyshyn‐Dylevych, A. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.05.062 · Cited by 65
One-step synthesis of 4(3H)-quinazolinones
Deetz, M. J., Malerich, J. P., Beatty, A. M., & Smith, B. D. (2001) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)00096-x · Cited by 65
Use of the in Vivo Hollow Fiber Assay in Natural Products Anticancer Drug Discovery
Mi, Q., Pezzuto, J. M., Farnsworth, N. R., Wani, M. C., Kinghorn, A. D., & Swanson, S. M. (2009) · Journal of Natural Products · doi:10.1021/np800767a · Cited by 64
Singh, R. K., Lange, T. S., Kim, K., & Brard, L. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9335-4 · Cited by 64
Synthesis of new potential anticancer agents based on 4-thiazolidinone and oleanane scaffolds
Kaminskyy, D. V., Bednarczyk–Cwynar, B., Vasylenko, O., Kazakova, O. B., Zimenkovsky, B. S., Zaprutko, L., & Lesyk, R. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9893-9 · Cited by 64
Denora, N., Laquintana, V., Lopalco, A., Iacobazzi, R. M., Lopedota, A., Cutrignelli, A., Iacobellis, G., Annese, C., Cascione, M., Leporatti, S., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.024 · Cited by 67
Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents
Subrahmanyam, D., Renuka, B., Rao, C. V., Sagar, P., Deevi, D. S., Babu, J. M., & Vyas, K. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00232-7 · Cited by 64
Recent Developments in Enediyne Chemistry
Joshi, M. C., & Rawat, D. S. (2012) · Chemistry & Biodiversity · doi:10.1002/cbdv.201100047 · Cited by 63
Elbadawi, M. M., Eldehna, W. M., Wang, W., Agama, K., Pommier, Y. G., & Abe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113261 · Cited by 63
Rajanarendar, E., Reddy, M. N., Krishna, S. R., Reddy, K. G., Reddy, Y. N., & Rajam, M. V. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.013 · Cited by 63
Danac, R. P., Matarneh, C. M. A., Shova, S. G., Daniloaia, T., Bălan, M., & Mangalagiu, I. I. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.077 · Cited by 63
2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazoles: Search for anticancer agents
Noolvi, M. N., Patel, H., Kamboj, S., Kaur, A., & Mann, V. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.012 · Cited by 63
Rajić, Z., Zorc, B., Raić‐Malić, S., Ester, K., Kralj, M., Pavelić, K., Balzarini, J. M., Clercq, E. D., & Mintas, M. (2006) · Molecules · doi:10.3390/11110837 · Cited by 63
Takebayashi, Y., Goldwasser, F., Urasaki, Y., Kohlhagen, G., & Pommier, Y. (2001) · PubMed · Cited by 63
Total Synthesis and Biological Evaluation of (−)Apicularen A and Analogues Thereof
Nicolaou, K. C., Kim, D. W., Baati, R., O’Brate, A., & Giannakakou, P. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200305230 · Cited by 63
Huang, R. S., Johnatty, S. E., Gamazon, E. R., Im, H. K., Ziliak, D. M., Duan, S., Zhang, W., Kistner, E. O., Chen, P., Beesley, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0724 · Cited by 67
Chan, P.-K. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.007 · Cited by 62
Sulphonamido-quinoxalines: Search for anticancer agent
Ingle, R. G., MARATHE, R. P., Magar, D., Patel, H., & Surana, S. J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.04.028 · Cited by 62
Mir, M., Bergamaschi, A., Katzenellenbogen, B. S., & Popescu, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089000 · Cited by 62
The first total synthesis of the cyclodepsipeptide pipecolidepsin A
Pelay‐Gimeno, M., García‐Ramos, Y., Martín, M. J., Spengler, J., Molina‐Guijarro, J. M., Munt, S. P., Francesch, A., Cuevas, C., Tulla‐Puche, J., & Alberício, F. (2013) · Nature Communications · doi:10.1038/ncomms3352 · Cited by 62
Wang, Z., Yang, D., Mohanakrishnan, A. K., Fanwick, P. E., Nampoothiri, P., Hamel, E., & Cushman, M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001119 · Cited by 62
Barbarić, M., Kralj, M., Marjanović, M., Husnjak, I., Pavelić, K., Filipović‐Grčić, J., Zorc, D., & Zorc, B. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.08.009 · Cited by 62
Natural Product Drug Discovery and Development: The United States National Cancer Institute Role
Cragg, G. M. L., Boyd, M. R., Khanna, R., Newman, D. J., & Sausville, E. A. (1999) · Springer eBooks · doi:10.1007/978-1-4615-4689-4_1 · Cited by 62
Self-citation7-Azaindenoisoquinolines as Topoisomerase I Inhibitors and Potential Anticancer Agents
Kiselev, E., DeGuire, S. M., Morrell, A. E., Agama, K., Dexheimer, T. S., Pommier, Y. G., & Cushman, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200719v · Cited by 61
Design, synthesis, and cytostatic activity of novel cyclic curcumin analogues
Youssef, D., Nichols, C. E., Cameron, T. S., Balzarini, J. M., Clercq, E. D., & Jha, A. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.079 · Cited by 61
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.